MAR 0 1 2004

maple

1635

Attorney Docket No. 59150-8010

I herewascertify that	correspondence is being dep	osited with the U.S. Postal Service with sufficient postage as hissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-
First Class Main A	envelope addressed to: Comm	issioner for Patents, P. O. Box 1450, Alexandria, VA 22313-
1450, on:	7	1/1 / 1
1 1	121 2114	Anna Bolad a a ma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Yasufumi Kaneda

SERIAL NO.: 09/937,839

FILED: February 21, 2002

FOR: VIRUS ENVELOPE VECTOR FOR GENE TRANSFER

EXAMINER: Whiteman, B

ART UNIT: 1635

CONFIRMATION NO. 7050

<u>Supplemental Information Disclosure Statement After Final Action or Notice of Allowance but Before Payment of Issue Fee – 37 CFR 1.97(d)</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

This information is being filed after a final Office action or a Notice of Allowance, whichever occurs first, but before payment of the Issue Fee.

2. Petition -37 CFR 1.97(d)

Applicant petitions the Patent and Trademark Office to accept this Information Disclosure Statement in light of the certification under 37 CFR 1.97(e) below, and payment of the fee under 37 CFR 1.97(d)(2).

j

Copies of the following references are enclosed: All cited references listed on PTO 1449 form References marked by asterisks The following:
Copies of the following references can be found in parent U.S. Application No. : All cited references References marked by asterisks The following:

03/04/2004 EHAILE1 00000054 09937839

4. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

5. <u>Certification Under 37 CFR 1.97(e)</u> (check one)

- In accordance with 37 CFR 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to this filing of this statement; or
- In accordance with 37 CFR 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c), more than three months prior to the filing of this statement.

6. Fee Payment $- 37 \text{ CFR} \cdot 1.97(d)(2)$

- Check enclosed for \$180.00 Information Disclosure Statement Fee as set forth in 37 CFR §1.17(p).
- Please charge any underpayment for timely filing of this paper to Deposit Account No. 50-2207.

7. Patent Term Adjustment (37 CFR 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of this statement. 37 CFR §1.704(d).


Respectfully submitted, Perkins Coie LLP

Date: <u>Feb. 26, 2004</u>

Jacqueline F. Mahoney Registration No. 48,390

Correspondence Address:

Customer No. 22918 Tel: 650 838-4410



					U.S. PATENT DOCUMEN	ITS	
Examiner Initials	Cite No.	,		ation nd Code known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date tor of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
	<u> </u>						
	<u> </u>			FC	PREIGN PATENT DOCUM	ENTS	
Examiner Initial	Cite No.	For	eign Patent or App NUMBER		e Name of Patentee or App	Date of Publication or Filing Date	Pages, Columns, Lines, Where Relevant Figures Appear T
-	· · · · · · · · · · · · · · · · · · ·				RT-NON PATENT LITERA		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.					
	ŧ		ni, K. <i>et al.</i> , "Ne p. 164-168, 19		e delivery to liver cells using	ng engineered viroson	nes," FEBS Letters
	,				nt method for DNA incorpo cts, 109(25):411, abstract 2		
						•	
	:						
			•				
# *	,					٠	,

EXAMINER		DATE CONSIDERED		
	1			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			